Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex has stepped up its interest in kidney disease over the past year, moving inaxaplin into a phase 2/3 AMKD trial at the start of April and inking a $4.9 billion deal to buy Alpine Immune ...

Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals VRTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Journavx costs $15.50 per 50 mg tablet, taken twice daily, making it pricier than opioids. Vertex's Q4 sales hit $2.91 billion, up 16% YoY, beating the $2.78 billion consensus. Next: Get access to ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, “Journavx has been placed on Tier 3 of the Optum ...

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio's top stock picks. The American ...

Nvidia (NVDA) CEO Jensen Huang took to the stage Tuesday afternoon to deliver his keynote speech at the chip giant's 2025 GTC event (GPU Technology Conference), where he previewed the company's ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...